235 related articles for article (PubMed ID: 19597368)
1. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
[TBL] [Abstract][Full Text] [Related]
2. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Bays HE; Maki KC; Doyle RT; Stein E
Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
5. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
Bays HE; Maki KC; McKenney J; Snipes R; Meadowcroft A; Schroyer R; Doyle RT; Stein E
Curr Med Res Opin; 2010 Apr; 26(4):907-15. PubMed ID: 20156032
[TBL] [Abstract][Full Text] [Related]
6. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Maki KC; Dicklin MR; Davidson MH; Doyle RT; Ballantyne CM;
Am J Cardiol; 2010 May; 105(10):1409-12. PubMed ID: 20451686
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
[TBL] [Abstract][Full Text] [Related]
14. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
15. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Farnier M; Roth E; Gil-Extremera B; Mendez GF; Macdonell G; Hamlin C; Perevozskaya I; Davies MJ; Kush D; Mitchel YB;
Am Heart J; 2007 Feb; 153(2):335.e1-8. PubMed ID: 17239698
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
18. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
19. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
20. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
